Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CK 0801

Next Previous
Drug Profile

CK 0801

Alternative Names: CK-0801

Latest Information Update: 12 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellenkos; University of Texas M. D. Anderson Cancer Center
  • Developer Cellenkos; University of Texas Health Science Center at Houston; University of Texas M. D. Anderson Cancer Center
  • Class T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aplastic anaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Bone marrow disorders
  • Discontinued Autoimmune disorders; Graft-versus-host disease; Guillain-Barre syndrome; Multiple sclerosis; Psoriasis; Type 1 diabetes mellitus

Most Recent Events

  • 22 May 2025 Cellenkos signs a strategic international memorandum of understanding (MOU) with King Faisal Specialist Hospital & Research Centre to develop T regulatory (Treg) cell therapies for Rare diseases
  • 21 Apr 2025 Discontinued - Phase-I for Graft-versus-host disease in USA (IV), before April 2025 (Cellenkos pipeline, April 2025)
  • 21 Apr 2025 Discontinued - Preclinical for Autoimmune disorders in USA (IV), before April 2025 (Cellenkos pipeline, April 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top